Account

Industry resources and insights

Sort by year
  • All time
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018 and older
News
13.02.2024
World EPA Congress 2024

The World Evidence, Pricing, and Access (EPA) Congress stands as Europe’s premier event in mar...

Read more
News
08.05.2024
My life with Asthma: understanding my world at wor...

Living with asthma is like having an unpredictable companion that can react at the slightest provoca...

Read more
Insider Insights
01.05.2024
Ground-breaking decision: first medicine ever with...

NHS takes a bold step towards achieving net zero by decommissioning desflurane due to its high globa...

Read more
News
26.04.2024
Beyond PMS: my journey for understanding and manag...

Navigating misdiagnosis and PMDD: A personal journey revealing severity, treatment, and support for ...

Read more
Insider Insights
23.04.2024
NICE Approves CAR-Therapy for NHS

NICE recommends Kymriah® for routine NHS use, offering immense benefits for those with resistant B-...

Read more
News
16.04.2024
The Juggling Act: A Working Mum’s Reflection

Training and Operations Manager, Sarah Bailey shares her experience of being a working mum, juggling...

Read more
Case Studies
02.04.2024
Securing the optimum launch price for a novel phar...

Looking to enhance your market access capabilities? Remap Consulting are the partner to help you lau...

Read more
Load more
Browse by topic
  • Biosimilars
  • Devices & Diagnostics
  • Digital Health
  • Early Access
  • Early Payer Dialogue
  • Emerging & Developing Markets
  • Funding
  • Gene Therapy & ATMPs
  • HTA
  • International Reference Pricing
  • Launch
  • Managed Entry Agreements
  • Medicine manufacturing
  • NICE
  • Oncology
  • Orphan Drugs
  • PMA Trends
  • Pricing
  • Rare Diseases
  • Real World Evidence
  • Team Remap
  • Tendering & Procurement
  • Training
Content type
  • All
  • Articles
  • Case Studies
  • Insider Insights
  • News
  • Publications
  • Webinar
Subscribe
Hidden
This field is for validation purposes and should be left unchanged.